Tudóstér: Treszl Andrea publikációi

PDF
-
szűkítés
feltöltött közlemény: 30 Open Access: 4
2017
  1. Sipos, É., Dull, K., Treszl, A., Steiber, Z., Méhes, G., Dobos, N., Molnár-Fodor, K., Oláh, G., Székvölgyi, L., Schally, A., Halmos, G.: Concurrence of chromosome 3 and 4 aberrations in human uveal melanoma.
    Oncol. Rep. 37 1927-1934, 2017.
    Folyóirat-mutatók:
    Q3 Cancer Research
    Q1 Medicine (miscellaneous)
    Q2 Oncology
2014
  1. Steiber, Z., Sipos, É., Dull, K., Halmos, G., Méhes, G., Treszl, A.: Aneuploidy of chromosome 3 and 4 in human uveal melanomas detected by fluorescence in situ hybridization.
    Invest. Ophthalmol. Vis. Sci. 55 6444, 2014.
  2. Mezey, G., Treszl, A., Schally, A., Block, N., Vízkeleti, L., Juhász, A., Klekner, Á., Nagy, J., Balázs, M., Halmos, G., Bognár, L.: Prognosis in human glioblastoma based on expression of ligand growth hormone-releasing hormone, pituitary-type growth hormone-releasing hormone receptor, its splicing variant receptors, EGF receptor and PTEN genes.
    J. Cancer Res. Clin. Oncol. 140 (10), 1641-1649, 2014.
    Folyóirat-mutatók:
    Q2 Cancer Research
    Q1 Medicine (miscellaneous)
    Q2 Oncology
2013
  1. Steiber, Z., Halmos, G., Cserháti, Z., Treszl, A.: Expression of stem cell markers in human uveal melanoma.
    Acta Ophthalmol. 91 s252, 2013.
  2. Treszl, A., Steiber, Z., Schally, A., Block, N., Dezső, B., Oláh, G., Rózsa, B., Molnár-Fodor, K., Buglyó, A., Gardi, J., Berta, A., Halmos, G.: Substantial expression of luteinizing hormone-releasing hormone (LHRH) receptor type I in human uveal melanoma.
    Oncotarget. 4 (10), 1721-1728, 2013.
    Folyóirat-mutatók:
    D1 Oncology
  3. Seitz, S., Buchholz, S., Schally, A., Jayakumar, A., Weber, F., Papadia, A., Rick, F., Szalontay, L., Treszl, A., Köster, F., Ortmann, O., Hohla, F.: Targeting triple-negative breast cancer through the somatostatin receptor with the new cytotoxic somatostatin analogue AN-162 [AEZS-124].
    Anti-Cancer Drugs. 24 (2), 150-157, 2013.
    Folyóirat-mutatók:
    Q3 Cancer Research
    Q2 Oncology
    Q2 Pharmacology
    Q2 Pharmacology (medical)
2011
  1. Steiber, Z., Treszl, A., Oláh, G., Buglyó, A., Rózsa, B., Berta, A., Halmos, G.: Expression of Receptors for Luteinizing Hormone-Releasing Hormone (LH-RH) in Human Uveal Melanomas.
    Invest. Ophthalmol. Vis. Sci. 52 6021, 2011.
  2. Kiss, C., Molnár, A., Treszl, A., Szegedi, I., Klekner, Á., Bognár, L., Dezső, B., Halmos, G.: Expression of receptors for luteinizing hormone-releasing hormone in pediatric neurogenic tumors.
    Pediatr. Blood Cancer. 57 (5), 783, 2011.
  3. Szilasi, M., Buglyó, A., Treszl, A., Kiss, L., Schally, A., Halmos, G.: Gene expression of vasoactive intestinal peptide receptors in human lung cancer.
    Int. J. Oncol. 39 (4), 1019-1024, 2011.
    Folyóirat-mutatók:
    Q2 Cancer Research
    Q1 Oncology
  4. Papadia, A., Schally, A., Halmos, G., Varga, J., Seitz, S., Buchholz, S., Rick, F., Zarándi, M., Bellyei, S., Treszl, A., Szalontay, L., Lucci, I.: Growth Hormone-Releasing Hormone Antagonists Inhibit Growth of Human Ovarian Cancer.
    Horm. Metab. Res. 43 (11), 816-820, 2011.
    Folyóirat-mutatók:
    Q2 Biochemistry
    Q1 Biochemistry (medical)
    Q2 Clinical Biochemistry
    Q2 Endocrinology
    Q2 Endocrinology, Diabetes and Metabolism
    Q1 Medicine (miscellaneous)
  5. Steiber, Z., Treszl, A., Rózsa, B., Berta, A., Halmos, G.: Receptors for luteinizing hormone-releasing hormone (LH-RH) in human uveal melanoma as potential molecular targets for cancer therapy.
    Acta Ophthalmol. 88 S246, 2011.
2010
  1. Barok, M., Balázs, M., Lázár, V., Rákosy, Z., Tóth, E., Treszl, A., Vereb, G., Colbern, G., Park, J., Szöllősi, J.: Characterization of a novel, trastuzumab resistant human breast cancer cell line.
    Front. Biosci. (Elite Ed). 1 (2), 627-640, 2010.
    Folyóirat-mutatók:
    Q2 Biochemistry, Genetics and Molecular Biology (miscellaneous)
    Q4 Immunology and Microbiology (miscellaneous)
    Q2 Medicine (miscellaneous)
2009
  1. Rózsa, B., Juhász, A., Treszl, A., Tóth, G., Flaskó, T., Dezső, B., Block, N., Schally, A., Halmos, G.: Expression of mRNA for human type-I LHRH receptor transcript forms in human benign prostatic hyperplasia.
    Int. J. Oncol. 35 (5), 1053-1059, 2009.
    Folyóirat-mutatók:
    Q2 Cancer Research
    Q1 Oncology
  2. Ziegler, C., Brown, J., Schally, A., Erler, A., Gebauer, L., Treszl, A., Young, L., Fishman, L., Engel, J., Willenberg, H., Petersenn, S., Eisenhofer, G., Ehrhart-Bornstein, M., Bornstein, S.: Expression of neuropeptide hormone receptors in human adrenal tumors and cell lines: Antiproliferative effects of peptide analogues.
    Proc. Natl. Acad. Sci. U.S.A. 106 (37), 15879-15884, 2009.
    Folyóirat-mutatók:
    D1 Multidisciplinary
  3. Márka, M., Semjéni, M., Treszl, A., Tóth, G., Flaskó, T., Dezső, B., Halmos, G.: Expression of somatostatin receptor subtypes in human bladder carcinoma.
    Acta Physiol. Hung. 96 (1), 100, 2009.
  4. Treszl, A., Schally, A., Seitz, S., Szalontay, L., Rick, F., Szepesházi, K., Halmos, G.: Inhibition of human non-small cell lung cancers with a targeted cytotoxic somatostatin analog, AN-162.
    Peptides. 30 (9), 1643-1650, 2009.
    Folyóirat-mutatók:
    Q2 Biochemistry
    Q4 Cellular and Molecular Neuroscience
    Q2 Endocrinology
    Q2 Physiology
  5. Seitz, S., Schally, A., Treszl, A., Papadia, A., Rick, F., Szalontay, L., Szepesházi, K., Ortmann, O., Halmos, G., Hohla, F., Buchholz, S.: Preclinical evaluation of properties of a new targeted cytotoxic somatostatin analog, AN-162 (AEZS-124), and its effects on tumor growth inhibition.
    Anticancer Drugs. 20 (7), 553-558, 2009.
    Folyóirat-mutatók:
    Q2 Cancer Research
    Q2 Oncology
    Q2 Pharmacology
    Q1 Pharmacology (medical)
2008
  1. Papadia, A., Schally, A., Seitz, S., Buchholz, S., Treszl, A., Szalontay, L., Halmos, G., Lucci, I.: Experimental therapy of ES-2 human platinum resistant ovarian cancer with targeted cytotoxic somatostatin and LHRH analogues.
    Gynecol. Oncol. 111 (2), 376, 2008.
  2. Seitz, S., Schally, A., Papadia, A., Ortmann, O., Buchholz, S., Treszl, A.: Inhibition of tumor growth of MDA-MB-231 human breast cancers by targeted cytotoxic analogue of somatostatin AN-162 (AEZS-124).
    Geburtshilfe Frauenheilkd. 68 S27, 2008.
  3. Szepesházi, K., Schally, A., Treszl, A., Seitz, S., Halmos, G.: Therapy of experimental hepatic cancers with cytotoxic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone, somatostatin or bombesin.
    Anticancer Drugs. 19 (4), 349-358, 2008.
    Folyóirat-mutatók:
    Q2 Cancer Research
    Q2 Oncology
    Q2 Pharmacology
    Q1 Pharmacology (medical)
  4. Barok, M., Balázs, M., Nagy, P., Rákosy, Z., Treszl, A., Tóth, E., Juhász, I., Park, J., Isola, J., Vereb, G., Szöllősi, J.: Trastuzumab decreases the number of circulating and disseminated tumor cells despite trastuzumab resistance of the primary tumor.
    Cancer Lett. 260 (1-2), 198-208, 2008.
    Folyóirat-mutatók:
    Q2 Cancer Research
    Q1 Oncology
2007
  1. Mile, M., Huga, S., Juhász, A., Treszl, A., Hernádi, Z., Halmos, G.: Bombesin/gastrin-releasing peptid receptorok mint molekuláris célpontok az endometriumkarcinóma kezelésében.
    Magyar Onkol. 51 (4), 364, 2007.
  2. Semjéni, M., Treszl, A., Huga, S., Juhász, A., Hernádi, Z., Halmos, G.: Szomatosztatin receptorok expressziójan és ezek jelentősége a humán endometriumkarcinóma célzott terápiájában.
    Magyar Onkol. 51 (4), 394, 2007.
2006
  1. Treszl, A., Ladányi, A., Rákosy, Z., Buczkó, Z., Ádány, R., Balázs, M.: Molecular cytogenetic characterization of a novel cell line established from a superficial spreading melanoma.
    Front. Biosci. 11 (1), 1844-1853, 2006.
    Folyóirat-mutatók:
    Q1 Biochemistry, Genetics and Molecular Biology (miscellaneous)
    Q1 Immunology and Microbiology (miscellaneous)
    D1 Medicine (miscellaneous)
2005
  1. Toida, M., Balázs, M., Rákosy, Z., Kató, K., Yamazaki, Y., Matsui, T., Suwa, T., Hatakeyama, D., Makita, H., Mori, S., Yamashita, T., Shibata, T., Ádány, R., Treszl, A.: Analysis of Ameloblastomas by Comparative Genomic Hybridization and Fluorescence in situ Hybridization.
    Cancer Genet. Cytogenet. 159 (2), 99-104, 2005.
    Folyóirat-mutatók:
    Q3 Cancer Research
    Q3 Genetics
    Q3 Molecular Biology
  2. Juhász, A., Balázs, M., Sziklai, I., Rákosy, Z., Répássy, G., Ádány, R., Treszl, A.: Chromosomal imbalances in laryngeal and hypopharyngeal cancers detected by comparative genomic hybridization.
    Cytometry A. 67 (2), 151-160, 2005.
    Folyóirat-mutatók:
    Q3 Cell Biology
    Q2 Histology
    Q1 Pathology and Forensic Medicine
2004
  1. Papadia, A., Schally, A., Seitz, S., Buchholz, S., Rick, F., Szalontay, L., Halmos, G., Treszl, A., Lucci, I.: Experimental therapy of ES-2 human platinum resistant ovarian cancer with growth hormone-releasing hormone antagonist JMR-132 or with targeted cytotoxic analog somatostatin AN-162.
    Gynecol. Oncol. 112 (2), S128-S129, 2004.
  2. Treszl, A., Ádány, R., Rákosy, Z., Kardos, L., Bégány, Á., Gilde, K., Balázs, M.: Extra copies of c-myc are more pronounced in nodular melanomas than in superficial spreading melanomas as revealed by fluorescence in situ hybridisation.
    Cytometry B. Clin. Cytom. 60B (1), 37-46, 2004.
    Folyóirat-mutatók:
    Q4 Cell Biology
    Q3 Histology
    Q3 Pathology and Forensic Medicine
  3. Balázs, M., Rákosy, Z., Bégány, Á., Ádány, R., Treszl, A.: Interphase cytogenetic analysis shows frequent hemizygous and homozygous deletion of p16/MTS1/CDKN2A tumorsuppressor gene in sporadic primary melanomas.
    Cytom. Part A. 59A (1), 69, 2004.
2001
  1. Balázs, M., Ádám, Z., Bégány, Á., Hunyadi, J., Treszl, A., Ádány, R.: Chromosomal imbalances in primary and metastatic melanomas revealed by comparative genomic hybridization.
    Cytometry. 46 (4), 222-232, 2001.
    Folyóirat-mutatók:
    Q2 Biophysics
    Q2 Cell Biology
    Q1 Endocrinology
    Q1 Hematology
    Q1 Pathology and Forensic Medicine
feltöltött közlemény: 30 Open Access: 4
https://tudoster.idea.unideb.hu
A szolgáltatást nyújtja: DEENK